Literature DB >> 18707241

The proline-rich region of HIV-1 Nef affects CXCR4-mediated chemotaxis in Jurkat T cells.

Carol Man Yuk Lee1, Salvador Gala, Graeme John Stewart, Peter Williamson.   

Abstract

T-cell chemotaxis constitutes an essential function of the immune response, since active secretion of chemokines controls homing and recruitment of leukocytes into tissues. Modification of chemotactic responses by HIV-1 may provide a mechanism to increase viral spread, and may be an important factor in HIV-1 disease progression and pathogenesis. One potent T-cell chemoattractant is SDF-1 alpha, the natural ligand for the HIV-1 co-receptor CXCR4. In addition, the HIV-1 gp120 molecule shares the chemotactic properties of several chemokines, including SDF-1 alpha. HIV-1 Nef is a pathogenic determinant and a virulence factor that has pleiotropic effects on immune cell processes and receptor signaling. In this study, the effects of Nef on T-cell migration to SDF-1 alpha, and on CXCR4 receptor signaling were examined. We report that disruption of the proline-rich region of Nef inhibits T-cell migration to SDF-1 alpha. This dominant negative effect indicates that Nef occupies a position in the CXCR4-mediated signaling pathway that is upstream of an SH3-dependent pathway. The results suggest that Nef may play an important role in homing of T cells during viral invasion in HIV-1 disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18707241     DOI: 10.1089/vim.2007.0093

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  2 in total

1.  HIV-1 Nef impairs heterotrimeric G-protein signaling by targeting Gα(i2) for degradation through ubiquitination.

Authors:  Prabha Chandrasekaran; Monica Buckley; Victoria Moore; Long Qin Wang; John H Kehrl; Sundararajan Venkatesan
Journal:  J Biol Chem       Date:  2012-10-15       Impact factor: 5.157

Review 2.  HIV-1 Infection of T Lymphocytes and Macrophages Affects Their Migration via Nef.

Authors:  Christel Vérollet; Véronique Le Cabec; Isabelle Maridonneau-Parini
Journal:  Front Immunol       Date:  2015-10-06       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.